#pharmaceuticalindustry #pharma #pharmaqc #pharmaquality #qualitycontrol #qualityassurance #gmp #usp429 To view or add a comment, sign in Common assumption: The FDA's recent actions on psychedelic treatments represent a minor regulatory tweak affecting only a handful of niche drugs and small biotech companies
Retatrutide, the triple agonist targeting GLP-1, GIP, and glucagon receptors, shows approximately 24% weight loss in phase 2 trials
Mortality rates range from about 15% in SJS to almost 30% in TEN
L-Carnitine is taken orally to treat or prevent certain conditions caused by carnitine deficiency, an inherited condition
In Phase 2 trials, the heart rate increases were not associated with a higher rate of serious adverse cardiac events
It supports normal heart and vascular function, supports healthy blood flow, and helps promote normal circulation